01/2022
Novel, first-in-class, fatty acid synthase (FASN) inhibitor TVB-2640 demonstrates robust clinical efficacy and safety in a global phase 2 randomized placebo-controlled NASH trial (FASCINATE-1)
NASH-TAG
Read More
11/2021
TVB-2640, a novel, first-in-class, fatty acid synthase (FASN) inhibitor: biomarker and metabolomic correlations with clinical MRI-PDFF response
NASH Summit
Read More
11/2021
Novel, first-in-class, fatty acid synthase (FASN) inhibitor TVB-2640 demonstrates robust clinical efficacy and safety in a global phase 2 randomized placebo-controlled NASH trial (FASCINATE-1) conducted in the U.S. and China
AASLD The Liver Meeting
Read More
11/2021
New Data from Sagimet’s Phase 2 FASCINATE-1 Clinical Trial Demonstrate TVB-2640’s Positive Effect Across Patients with NASH in the U.S. and China
San Mateo, California, November 12, 2021 – Sagimet Biosciences, a clinical-stage biotechnology company, announced today that Rohit Loomba, MD, MHSc, Director, NAFLD Research Center, University of California San Diego, will…
Read More
10/2021
Sagimet to Present Data from Phase 2 FASCINATE-1 Trial of TVB-2640 in NASH at AASLD’s The Liver Meeting 2021
FOR IMMEDIATE RELEASE San Mateo, California, October 4, 2021– Sagimet Biosciences, a clinical-stage biotechnology company, announced today that consolidated results from its Phase 2 FASCINATE-1 trial of TVB-2640 in patients…
Read More
09/2021
Translation of FASN Inhibitor TVB-2640 from Preclinical MOA to Clinical POC in NASH
NASH and Fibrosis Conference
Read More
08/2021
Sagimet Biosciences Doses First Patient in FASCINATE-2 Phase 2b Trial in NASH Patients with Moderate to Advanced Fibrosis
FOR IMMEDIATE RELEASE San Mateo, California, August 16, 2021 – Sagimet Biosciences, a clinical-stage biotechnology company focused on developing a portfolio of internally-discovered, selective fatty acid synthase (FASN) inhibitors, announced today…
Read More
07/2021
Published Results from Sagimet’s FASCINATE-1 Phase 2a Trial Demonstrate FASN Inhibitor TVB-2640’s Ability to Significantly Reduce Excess Liver Fat
San Mateo, California, July 26, 2021 – Sagimet Biosciences Inc., a clinical-stage biotechnology company focused on developing a portfolio of internally-discovered, selective fatty acid synthase (FASN) inhibitors, announced today that Gastroenterology…
Read More
07/2021
TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled Ph2a trial
Gastroenterology
Read More